Impact of the hyperbaric oxygen therapy on the redox status  in the patients with systemic lupus erythematosus

Milorad  Rabrenović; Tamara Nikolić; Violeta Rabrenović; Jovana Bradić; Saša Trešnjić; Anica Petković; Biljana Jakovljević; Siniša Mašić; Dubravko Bokonjić

doi:10.2298/VSP170110106R

Milorad Rabrenović Military Medical Academy, Center of Hyperbaric Medicine, Belgrade, Serbia
Tamara Nikolić University of Kragujevac, Faculty of Medical Science, Department of Pharmacy, Kragujevac, Serbia
Violeta Rabrenović Military Medical Academy, Clinic of Nephrology, Belgrade, Serbia
Jovana Bradić University of Kragujevac, Faculty of Medical Science, Department of Pharmacy, Kragujevac, Serbia
Saša Trešnjić Military Medical Academy, Center of Hyperbaric Medicine, Belgrade, Serbia
Anica Petković University of Kragujevac, Faculty of Medical Science, Department of Pharmacy, Kragujevac, Serbia
Biljana Jakovljević Military Medical Academy, Institute of Hygine, Belgrade, Serbia
Siniša Mašić Military Medical Academy, Institute of Hygine, Belgrade, Serbia
Dubravko Bokonjić University of Defence, Faculty of Medicine of the Military Medical Academy, Belgrade, Serbia

DOI: https://doi.org/10.2298/VSP170110106R

Keywords: hyperbaric oxygenation;, lupus erythematosus;, oxidation-reduction;, oxidative stress.

Abstract

Background/Aim. Hyperbaric oxygen therapy (HBOT) is a method which increases oxygen solubility in plasma up to 20 times. This effect is very important in the treatment of circulatory disorders, which reduces oxygenation and leads to increased production of inflammatory mediators and free oxygen radicals. The aim of this study was to examine the impact of HBOT on the oxidative stress parameters in the patients with systemic lupus erythematosus (SLE). Methods. This prospective study included 18 females with SLE [American College of Rheumatology (ACR) criteria], average age 52.2 ± 8.82 years, treated with HBOT for 60 min/day, with average partial oxygen pressure of 2.2 atmospheres absolute (ATA), during 10 days, in combination with appropriate medication therapy for SLE. The following parameters were determined in the serum: C-reactive protein (CRP), hemoglobin, creatinine, albumin, complement 3 (C3), antinuclear antibodies (ANA), glomerular filtration rate (GFR) using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula. In the urine, parameters of oxidative stress were spectrofotometrically determined: levels of superoxide anion radical (O₂^·–), hydrogen peroxide (H₂O₂), nitrites (NO₂^-) and concentration of thiobarbituric acid reactive substances (TBARS). In hemolysate, the parameters of antioxidant protection: superoxide dismutase (SOD), catalase (CAT) and reduced gluthatione (GSH), were measured. The samples for the analysis were collected three times: before HBOT (initial values), after 10 days of HBOT and 1 month after beginning the treatment in relation to the initial value. Results. We noticed a statistically significant (p < 0.05) decrease in a level of O₂^·–, both after 10 days and after 1 month of HBOT (8.26 ± 13.62; 8.39 ± 4.94; 11.92 ± 6.86 nmol/mL, respectively). Values of other parameters of oxidative stress such as NO₂^-, TBARS and H₂O₂^- showed no significant difference during the monitored period. Regarding the parameters of antioxidant the protection, we revealed slightly higher value of GSH after treatment (initial value: 66.34 ± 16.31; after 10 days of HBOT 79.43 ± 36.77; after 1 month of HBOT69.72 ± 22.32 μmol/mL red blood cells) which was held after a month, but it was not statistically significant. Activity of SOD and CAT, before and after HBOT, did not change significantly. Conclusion. Our results suggested the potential beneficial effects of HBOT on redox status in the patients with SLE by decreasing the levels of O₂^·–.

References

REFERENCES

Adinolfi A, Valentini E, Calabresi E, Tesei G, Signorini V, Barsotti S et al. One year in review 2016: systemic lupus ery-thematosus. Clin Exp Rheumatol 2016; 34(4): 569–74.

Shah D, Mahajan N, Sah S, Nath SK, Paudyal B. Oxidative stress and its biomarkers in systemic lupus erythematosus. J Biomed Sci 2014; 21(1): 23.

Mansour RB, Lassoued S, Gargouri B, Gaïd EA, Attia H, Fakh-fakh F. Increased levels of autoantibodies against catalase and su¬peroxide dismutase associated with oxidative stress in pa-tients with rheumatoid arthritis and systemic lupus erythema-tosus. Scand J Rheumatol 2008; 37(2): 103–8.

Avalos I, Chung CP, Oeser A, Milne GL, Morrow JD, Gebretsadik T, et al. Oxidative stress in systemic lupus erythematosus: rela-tionship to disease activity and symptoms. Lupus 2007; 16(3): 195–200.

Shah D, Kiran R, Wanchu A, Bhatnagar A. Oxidative stress in sys¬temic lupus erythematosus: relationship to Th1 cytokine and disease activity. Immunol Lett 2010; 129(1): 7–12.

Gilkeson G, Cannon C, Oates J, Reilly C, Goldman D, Petri M. Cor¬relation of serum measures of nitric oxide production with lu¬pus disease activity. J Rheumatol 1999; 26(2): 318–24.

Oates JC, Shaftman SR, Self SE, Gilkeson GS. Association of se-rum nitrate and nitrite levels with longitudinal assessments of disease activity and damage in systemic lupus erythematosus and lupus nephritis. Arthritis Rheum 2008; 58(1): 263–72.

Wanchu A, Khullar M, Sud K, Sakhuja V, Thennarasu K, Sud A, et al. Serum and urine nitrite and citrulline levels among pa-tients with systemic lupus erythematosus: a possible addition to ac¬tivity parameters?. J Clin Rheumatol 2001; 7(1): 10–5; discus¬sion 15.

Stanisavljevic N, Stojanovich L, Marisavljevic D, Djokovic A, Dopsaj V, Kotur-Stevuljevic J, et al. Lipid peroxidation as risk factor for endothelial dysfunction in antiphospholipid syndrome pa-tients. Clin Rheumatol 2016; 35(10): 2485–93.

Kumar MA, Radhika B, Gollamudi N, Reddy SP, Yaga US. Hy-per¬baric Oxygen Therapy: A Novel Treatment Modality in Oral Submucous Fibrosis: A Review. J Clin Diagn Res 2015; 9(5): ZE01–4.

Bhutani S, Vishwanath G. Hyperbaric oxygen and wound heal-ing. Indian J Plast Surg 2012; 45(2): 316–24.

Camporesi EM, Bosco G. Mechanisms of action of hyperbaric oxy¬gen therapy. Undersea Hyperb Med 2014; 41(3): 247–52.

Boykin JV, Baylis C. Hyperbaric oxygen therapy mediates in-creased nitric oxide production associated with wound heal-ing: a preliminary study. Adv Skin Wound Care 2007; 20(7): 382–8.

Health Quality Ontario. Hyperbaric oxygen therapy for non-heal¬ing ulcers in diabetes mellitus: an evidence-based analysis. Ont Health Technol Assess Ser 2005; 5(11): 1–28.

Rabrenović M, Matunović R, Rabrenović V, Zoranović U. Hyperbar-ic medicine: dilemmas regarding its possibilities. Vojnosanit Pregl 2008; 65(3): 235–8. (Serbian)

Efrati S, Bergan J, Fishlev G, Tishler M, Golik A, Gall N. Hy-per¬baric oxygen therapy for nonhealing vasculitic ulcers. Clin Exp Dermatol 2007; 32(1): 12–7.

Olivieri AN, Mellos A, Duilio C, Di Meglio M, Mauro A, Perrone L. Refractory vasculitic ulcer of the toe in an adolescent suf-fering from systemic lupus erythematosus treated successfully with hyperbaric oxygen therapy. Ital J Pediatr 2010; 36: 72.

Guidelines for referral and management of systemic lupus ery-thematosus in adults. American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Guide-lines. Arthritis Rheum 1999; 42(9): 1785–96.

Tunnicliffe DJ, Singh-Grewal D, Kim S, Craig JC, Tong A. Diag-no¬sis, Monitoring, and Treatment of Systemic Lupus Erythe-ma¬tosus: A Systematic Review of Clinical Practice Guidelines. Arthritis Care Res (Hoboken) 2015; 67(10): 1440–52.

Auclair C, Voisin E. Nitroblue tetrazolium reduction. In: Greenwald RA, editor. Handbook of methods for oxygen radi-calresearch. Boca Raton: CRC Press; 1985. p. 123–32.

Pick E, Keisari Y. A simple colorimetric method for the meas-urement of hydrogen peroxide produced by cells in culture. J Immunol Methods 1980; 38(1–2): 161–70.

Green LC, Wagner DA, Glogowski J, Skipper PL, Wishnok JS, Tan¬nenbaum SR. Analysis of nitrate, nitrite, and [15N] nitrate in biological fluids. Anal Biochem 1982; 126(1): 131–8.

Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in ani-mal tissues by thiobarbituric acid reaction. Anal Biochem 1979; 95(2): 351–8.

McCord JM, Fridovich I. The utility of superoxide dismutasein studying free radical reactions. I. Radicals generated bythe in-teraction of sulfite, dimethyl sulfoxide, and oxygen. J Biol Chem 1969; 244(22): 6056–63.

Beutler CE. Red cell metabolism, a manual of biochemical meth¬ods. In: Beutler E, editor. New York: Grune and Strat-ton; 1982. p. 105–6.

Misra HP, Fridovich I. The role of superoxide anion in the au-toxi¬dation of epinephrine and a simple assay for superoxide dismutase. J Biol Chem 1972; 247(10): 3170–5.

Beutler E. Reduced glutathione (GSH). In: Beutler E, editor. Red Cell Metabolism, a Manual of Biochemical Methods. New York, NY, USA: Grune and Stratton; 1975. p. 112–4.

Thom SR. Oxidative stress is fundamental to hyperbaric oxy-gen therapy. J Appl Physiol 2009; 106(3): 988–95.

Gošović S. Foundations of Military and Underwater Medicine with Respiratory Protection. Split: Medicinska naklada; 2000. (Croatian)

Allen RG, Balin AK. Oxidative influence on development and differentiation: an overview of a free radical theory of devel-opment. Free Radic Biol Med 1989; 6(6): 631–61.

Dennog C, Radermacher P, Barnett YA, Speit G. Antioxidant sta-tus in humans after exposure to hyperbaric oxygen. Mutat Res 1999; 428(1–2): 83–9.

Aringer M, Schneider M. Management of systemic lupus erythe-matosus. Internist (Berl) 2016; 57(11): 1052–9.

Crow MK. Etiology and pathogenesis of systemic lupus erythe-matosus. In: Firestein GS, Budd RC, Gabriel SE, Mcinnes IB, O'Dell JR, et al, editors. Kelley's Textbook of Rheumatology. 9th ed. Philadelphia, PA: Elsevier Saunders; 2013: Chap 79.

Yatsuzuka H. Effects of hyperbaric oxygen therapy on ischem-ic brain injury in dogs. Masui 1991; 40(2): 208–23. (Japanese)

Jou Y, Lien F, Cheng M, Shen C, Lin C, Chen P. Hyperbaric ox-y¬gen therapy for cyclophosphamide-induced intractable refrac-tory hemorrhagic cystitis in a systemic lupus erythematosus pa-tient. J Chin Med Assoc 2008; 71(4): 218–20.

Ozden TA, Uzun H, Bohloli M, Toklu AS, Paksoy M, Simsek G, et al. The effects of hyperbaric oxygen treatment on oxidant and antioxidants levels during liver regeneration in rats. Tohoku J Exp Med 2004; 203(4): 253–65.

Yasar M, Yildiz S, Mas R, Dundar K, Yildirim A, Korkmaz A, et al. The effect of hyperbaricoxygen treatment on oxidative stress in experimentalacute necrotizing pancreatitis. Physiol Res 2003; 52(1): 111–6.

Kudchodkar BJ, Wilson J, Lacko A, Dory L. Hyperbaricoxygen re¬duces the progression and accelerates theregression of ather-o¬sclerosis in rabbits. Arterioscler Thromb Vasc Biol 2000; 20(6): 1637–43.

Gulec B, Yasar M, Yildiz S, Oter S, Akay C, Deveci S, et al. Ef-fect of hyperbaricoxygen on experimental acute distal colitis. Physiol Res 2004; 53(5): 493–9.

Gregorevic P, Lynch GS, Williams DA. Hyperbaric oxygen mod-u¬lates antioxidant enzyme activity in rat skeletal muscles. Eur J Appl Physiol 2001; 86(1): 24–7.